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Novel Localized Drug Delivery Methods to Enhance Post Orthodontic Retention 
Siyouneh Novshadian 
Abstract 
Post-orthodontic relapse remains a challenging and undesirable consequence of 
orthodontic treatment. Relapse occurs in part due to the presence of relatively immature 
bone in the direction of tooth relapse that can be readily resorbed by osteoclasts. 
Because current approaches to retain tooth alignment have well-known caveats, recent 
studies, including several from our group, have explored the utility of biologic agents 
such as osteoprotegerin (OPG) in mitigating post-orthodontic relapse. In proof-of-
concept studies the repeated submucosal injection of naked OPG resulted in a 3.5-fold 
increase in post-orthodontic tooth stability. In contrast, the administration of a single 
dose of OPG-loaded PLGA microbeads contributed only to modest increases in tooth 
stability. This was attributed to an initial bolus release of OPG from the delivery system. 
Therefore, the goal of the current study was to design and test in vitro other methods of 
drug delivery for slow sustained release of OPG at optimal concentrations to have 
clinical efficacy. We tested the hypothesis that optimally constituted OPG-loaded 
polythelyne glycol (PEG) nanoparticles would result in a slow, sustained, and optimal 
release of OPG in vitro.  We also designed and tested a novel method of intraoral drug 
delivery using thin film devices. The microspheres were loaded with 330µg of OPG into 
PEG microspheres and were placed in PBS and the eluated assayed every day for 28 
days. The findings showed gradually decreasing but sustained release of OPG over a 
28 day period. Further enhancements in PEG microsphere fabrication and OPG 
concentrations will be instituted for ongoing studies to optimize the release kinetics. The 
thin films were constructed from polyethylene glycol, customized to fit onto the rat palate 
iii
and loaded with 90µg of OPG. Following further enhancements to the PEG 
microspheres,  thin film fabrication, and optimization of OPG release kinetics, these 
delivery systems will be tested for their efficacy in enhancing tooth stability in a rat 
model for orthodontic relapse.   
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Introduction 
The stability of teeth following orthodontic treatment remains a challenge due to 
the natural tendency for teeth to move towards their original positions. Orthodontic 
relapse is an undesirable tendency for teeth to return to or move towards their 
pretreatment positions after having been moved through bone. This instability is a 
significant limitation to treatment outcomes due to the negative effects on tooth 
alignment and esthetics, the high rate at which it occurs, and its impact on patient 
satisfaction and significant financial burden on patients who require re-treatment. As 
current methods of enhancing stability, such as retainer wear, rely on long term patient 
compliance, orthodontic relapse remains a prevalent issue. While the cause(s) of 
orthodontic relapse remain poorly understood, of the many theorized contributions to 
relapse, bone quality and maturity is thought to be a major component.1 Gaining a 
better understanding of the biologic processes that occur within the bone following 
orthodontic treatment and during the stabilization period could provide us with direction 
toward more effective preventive or therapeutic strategies.  
According to the widely accepted “pressure-tension” theory of orthodontic tooth 
movement, the periodontal ligament (PDL) is compressed on the pressure side which is  
the side in the direction the force is being applied, and thus, the direction of the tooth 
movement. This compression of the PDL leads to metabolic changes such as the 
decrease in blood flow and oxygen molecules, and increase in carbon dioxide. These 
metabolic changes signal specific cytokines to induce osteoclastic activity to begin 
resorbing the bone in the direction of the force application – a process known as 
osteoclast mediated resorption.2,3  
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Specifically, Interleukin-1, beta (IL-1β), PGE2, and IL-6 are the cytokines thatplay 
critical roles in the early processes of activating osteoclast precursor cells via nuclear 
factor kappa B (RANK) and nuclear factor kappa B ligand (RANKL) proteins.4  In 
addition, osteoblastic cells also play a role in promoting more osteoclastic differentiation 
by synthesizing RANKL.5 The surface expression of RANKL on osteoblast cells 
communicates with osteoclastic precursor cells expressing the RANK receptor to induce 
osteoclast differentiation and activation.6   
To add to this knowledge of orthodontic tooth movement, a newer theory called 
the “stretched fiber hypothesis” suggests that the elastic fibers in the PDL should be 
considered when conceptualizing tooth movement. Given that PDL fibers are of elastic 
nature, when they are compressed, they exert less force on the adjacent bone. That 
lack of compression on the adjacent bone may be the cause of bone resorption. This 
concept aligns with the mechanostat theory in which it is hypothesized that low strain of 
bone leads to bone resorption.7 
Simultaneously, osteoblast-mediated bone deposition occurs on the opposite 
side of the tooth roots in the area from which the tooth moved by similar 
communications and processes via cytokines. This cascade of events results in tooth 
movement.8 Conceptually, in order for relapse to occur towards the pre-treatment tooth 
position, the newly formed and relatively immature bone deposited by osteoblasts 
adjacent to the tooth must be resorbed by osteoclasts. Thus, biologics or drugs that 
contribute to enhanced or accelerated bone synthesis and maturation or drugs that 
minimize bone resorption by osteoclasts could be of high therapeutic value in increasing 
post-orthodontic stability of teeth.   
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Over the years, several biologics that either primarily increase bone synthesis or 
decrease bone resorption have been used to test the inhibition of tooth movement for 
increased anchorage or decreased relapse in animal models. These include 
bisphosphonates,9 nitric oxide synthase inhibitor,10 echistatin,11 MMP inhibitor,11,12 
osteoprotegerin (OPG) gene13 or OPG protein.14–17 Of these, several such as 
bisphosphonates and estradiol have substantial caveats, including potential systemic 
effects whereas others were not found to have substantial efficacy in modulating tooth 
movement. In contrast, the use of OPG has been widely studied and has been shown to 
greatly limit relapse with no discernible systemic effects on long bones.Osteoclast 
activation is initiated by the binding of RANKL to the RANK receptor found on osteoclast 
precursor cells.3 OPG is a known decoy receptor for RANKL and acts as a competitive 
inhibitor of RANK thereby inhibiting osteoclastogenesis and bone resorption.3 It was first 
used to slow down bone resorption by inhibiting RANKL expression of osteoclasts in a 
study on postmenopausal women.18 In additional studies, it was shown to reduce bone 
resorption systemically in several diseases including Paget’s disease, rheumatoid 
arthritis, hypercalcemia of malignancy, osteolytic metastases, postmenopausal bone 
loss and periodontal disease.14,18–22 Our previous studies have combined this 
knowledge with the concept of bone resorption occurring in the direction of tooth 
movement to evaluate the mechano-modulation of bone modeling using OPG. 
Specifically, by exploring its potential to alter tooth movement, reduce orthodontic 
relapse, and enhance anchorage.14–16  
Once it was noted that OPG could inhibit bone resorption via a systemic 
approach, its local effects on orthodontic tooth movement were explored in an animal 
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model utilizing a low dose of 0.5 mg/kg OPG and high dose of 5 mg/kg OPG to test 
molar anchorage in rats and compared them to control animals receiving Phosphate 
Buffered Saline (PBS) (Dunn et al., 2007). The animals received orthodontic force 
application in the form of nickel titanium springs ligated to the maxillary first molars and 
incisors (Fig. 1) for 28 days with twice weekly injections of either the low or high dose of 
OPG via local infiltration to the mucosa surrounding the molars. Tooth movement 
measurements were taken using stone models that were scanned and measured 
digitally. Measurements were taken pre-treatment, during treatment, and post-treatment. 
Administration of low and high dose OPG both resulted in a decrease in mesial 
movement of the first molar when compared to control animals. When compared to 
controls, the high dose OPG treatment resulted in a 79% decrease in mesial movement 
of the first molar, suggesting an enhancement in molar anchorage.14 This inhibition of 
tooth movement likely resulted from an inhibition of osteoclastogenesis and was 
supported by the histologic microCT findings showing enhanced bone quality, as well as 
immunohistochemical analysis and serum TRAP-5b staining in animals treated with 
OPG vs the controls.  
Following this discovery, this group of investigators led by Dr. Sunil Kapila 
became interested in the ability of OPG to enhance post-orthodontic stability. The same 
animal model of spring-force application was used, however, OPG was administered 
following 28 days of tooth movement when the appliances were removed, thus testing 
post-orthodontic stability and inhibition of relapse. The animals were injected with either 
5 mg/kg OPG, 1 mg/kg OPG, or PBS at several time points after appliances were 
removed, and monitored for 24 days (Fig. 2).  In addition to  histology, serum Trap-5b 
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analysis, and microCT, tooth movement measurements were taken every 4 days. Both 
the high dose and low dose groups showed significant reduction in tooth movement with 
no significant differences between the high and low dose groups. While the control 
group experienced 63% relapse, the low and high dose OPG treated groups 
experienced 24% and 31% relapse, respectively. The histology performed on these 
animals showed that all three groups experienced a widening of the PDL space at 
compression sites, which the investigators concluded accounted for the major relapse of 
43% seen within the first two days.  No osteoclastic activity was observed in this two-
day period, which signified that this rebound period is not attributed to bone remodeling, 
and therefore cannot be altered by bone modulating agents. Once this rebound 
percentage was accounted for, the adjusted relapse percentage was 3.5 times lower in 
the low dose and 40-fold lower in the high dose group than in PBS controls (13 and 
-1.6%). In addition, improvements in bone quality were observed by microCT and 
histology. The study concluded that OPG enhanced post-orthodontic stability in rats 
when repeatedly administering either at a high dose of 5 mg/kg or low dose of 1 mg/kg 
OPG.15  
A follow-up study was performed  to determine the appropriate single 
submucosal OPG dose when delivered following tooth movement that would inhibit 
post-treatment relapse while limiting its effects to the site of injection and concomitantly 
showing no or little systemic effects (Schneider et al., 2015). The same animal model 
described previously was used, utilizing a single high dose of 1 mg/kg and low dose of 
0.1 mg/kg injection after 28 days of tooth movement. This study investigated the local vs 
distant effects of OPG by comparing molar relapse to incisor relapse given that the 
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injection was delivered to the mucosa of the molar. The incisors were found to relapse 
up to 95% after 28 days. In contrast the single injection of 0.1 mg/kg or 1 mg/kg OPG 
resulted in a dose-dependent reduction in post-orthodontic relapse by 40% and 60%, 
respectively, at the end of the experimental period, while having little to no effect on the 
relapse of the incisors.16 Histology also confirmed an increase in osteoclast presence 
using Trap5b staining when compared to pre-treatment animals, and a return to 
baseline presentation for all groups after 24 days suggesting the OPG injected was non-
active after 24 days of relapse. MicroCT analysis of the rat femurs at the end of the 
experimental period showed no significant differences in any of the bone quality 
measures between the three groups, suggesting OPG does not produce long-lasting 
systemic effects. The results of this study demonstrate that a single dose of OPG is 
adequate in significantly mitigating orthodontic relapse with limited effects on tooth 
movement in the neighboring sites.  
Towards a clinical translation of these findings, more controlled, localized, and 
sustained drug delivery and preferably non-invasive methods are needed to optimize 
the effects of OPG while maintaining minimal to no systemic effects. Also, although 
these proof of concept studies cited above found improvements in stability of tooth 
movement using OPG when compared to controls, they did not generate the desired 
complete inhibition of relapse. The application of drug delivery methods for modulating 
orthodontic tooth movement has been explored only very recently.17   
Microspheres are an emerging advancement of drug delivery methods that have 
gained attention in the biomedical field due to their biocompatibility and their potential as 
therapeutic agent carriers.23  Using these methods, the desired drug release kinetics 
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can be controlled by parameters such as molecular weight, ratio of polymers, and drug 
concentration.24 This approach has been used in one recent study where the rate of 
release of OPG was regulated over a longer duration of time using OPG embedded in 
polylactic-co-glycolic acid (PLGA) microspheres. The in vivo finding using our model of 
orthodontic anchorage (Dunn et al., 2007) revealed that that injection of 1 mg/kg of 
OPG encapsulated in PLGA polymer microspheres enhances molar stability relative to 
the same dose of unencapsulated OPG, suggesting that the slower release of OPG 
may be more efficacious than an immediate-release OPG in preserving tooth positional 
stability. Despite these promising findings, the release of OPG from the microspheres 
lacked consistency and was relatively quick with 50% OPG released within 2.5 days. 
Concomitantly, the efficacy of this delivery method was relatively modest with 26% less 
molar movement relative to that with unencapsulated OPG or vehicle controls. This 
suggests that alternative drug delivery systems that offer sustained and more constant 
release profiles of the agent may contribute to increased efficacy in reducing relapse. 
Additionally, the delivery of the drug via non-invasive methods rather than by injection 
will likely make the proposed approaches to therapy more acceptable to the patient and 
clinician over that offered by invasive methods.  
The goal of this Master’s thesis work was to expand upon previous findings 
towards clinical applications by fabricating and in vitro testing of drug delivering devices 
in order to achieve a highly regulated slow and sustained release of OPG, and 
subsequently compare its in vivo effects to that immediate-release of OPG. The longer-
term goal of our studies is to develop drug delivery systems and subject these to in vivo 
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and clinical trials for use in orthodontic applications in mitigating relapse and modulating 
tooth movement.  
 In comparison to PLGA microspheres, polyethylene glycol (PEG) based 
microparticles offer better control and release dynamics for sustained release of drugs, 
as has been shown previously.25–28 Although PLGA microspheres are the most 
commonly used polymers, they have certain limitations due to the hydrophobic nature of 
PLGA polymers including protein denaturation and adsorption to their hydrophobicity. 
For long term release, a hydrophilic bioinert copolymer such as PEG is advantageous 
given the slower degradation process. Its degradation process is slower due to the 
inorganic copolymers it contains which make it more difficult for the body to breakdown 
and thus, release the drug into the system. PEG based microparticles are ideal because 
of their injectable form, biocompatibility, and the relative simplicity in drug, protein, and 
cell encapsulation.25–28  
Briefly, a microfluidic system with rounded fluid channels is used to create 
monodisperse PEG microparticles that ultimately form microspheres.29,30 Proteins 
encapsulated in PEG microspheres exhibit drug release kinetics over a period of time 
that is ideal for our application, ranging from hours to weeks,25–27,31 contingent on PEG 
precursor solution composition. Since this method has already been shown to satisfy 
our criteria for administration and potentially for optimal release kinetics of anti-relapse 
therapeutics, we have selected this approach as our primary method to test for 
fabrication and in vitro testing of drug delivery.   
Additionally, the delivery of the drug via non-invasive methods rather than by 
injection will likely make the proposed approaches to therapy more acceptable to the 
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patient and clinician over that offered by invasive methods. In this context, the use of 
nanoengineered membranes is a promising approach to provide sustained release of 
proteins and small molecules. In addition to their ability to provide sustained release, 
they can be delivered without implantation and therefore, provide a non-invasive 
approach. Given the porous mucous membranes of the oral cavity, we anticipate the 
drug to be released rather easily without implantation. Previous work with these devices 
have demonstrated release over several months with a highly controlled zero-order 
release rate (i.e. constant rate drug release).32,33,34,35,36 Zero-order kinetics enables tight 
control of target drug concentrations. As opposed to our observations when delivering 
OPG in PLGA polymer microspheres, this method eliminates the initial bolus excess 
and the late sub-therapeutic decline, while maximizing the available drug payload.  
Briefly, thin film membranes are fabricated by spin- or draw-casting a polymer 
solution, which generates highly controlled films from 10-100 µm thick. These 
techniques can be further combined with pore-forming agents or sacrificial templates to 
generate a wide range of micro- and nano-structures. Such polymeric thin films can 
then be fabricated into devices with a variety of form factors, which can be suited for 
delivery in confined spaces (Fig. 4). Thin devices fabricated from biodegradable 
polymer, polycaprolactone (PCL), can naturally degrade and avoid later invasive device 
removal. Previous work with these thin films in ocular devices and cell-based therapies 
have demonstrated good biocompatibility across applications.37,38,39 In addition, these 
devices were developed to decouple the material fabrication from the drug formulation, 
allowing optimization of drug stability and payload in parallel with required release rate 
(Fig. 5). Our goal is to use these approaches to achieve sustained and constant delivery 
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of biologics for preserving post-orthodontic tooth stability in our rat model. However, first 
novel methods of design and delivery need to be established given that thin films have 
never been tested in the oral cavity. We will first design a device to be placed in an 
animal tooth movement model in the oral cavity, away from occlusal forces and fastened 
to hard or soft tissues to prevent dislodging. In this study, we plan to take advantage of 
the emerging advances in nanoparticle delivery and improve on the previous protocols 
by testing two new novel methods of delivery: PEG microspheres and thin film devices. 
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Central Hypothesis 
We hypothesize that PEG microspheres and thin film devices are effective methods for 
localized, non-invasive, and controlled release of agents into oral tissue for use in 
mitigating orthodontic relapse. 
11
Specific Aims 
1. Design and fabricate PEG microsphere delivery system that will result in 
desirable long-term release kinetics of optimal OPG concentrations over 14 to 30 
days for subsequent use in vivo studies using the orthodontic relapse rat model.   
2. Undertake initial studies on designing and fabricating thin film devices for 
intraoral applications in the rat for subsequent in vitro and in vivo testing to 
deliver optimal sustained release of OPG. 
These studies will lay the foundations for future investigations to test the efficacy of 
these OPG delivery systems in mitigating orthodontic relapse in animal studies and 
possibly in human trials.  
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Material and Methods 
Materials 
 Poly(ethylene glycol) dimethacrylate (PEG-DMA) (MW 750), 1- vinyl-2-
pyrrolidinone, containing sodium hydroxide as inhibitor (MW 111.14) and 2,2- Dimethoxy 
-2-phenylacetophenone (MW 256.30) were purchased from Sigma Aldrich (St. Louis, 
MO). Osteoprotegrin (OPG) (60kDa) was generously provided by Amgen Corporation at 
a concentration of 18.85 mg/mL with a 100% buffer solvent.  
Equipment 
 A micro BCA assay kit from Thermofisher Scientific was used to quantify the 
concentration of protein release daily in the supernatant. Assays were performed using 
a SpectraMaxM2E plate reader.  
Microsphere fabrication 
 OPG in the concentration of 18.85 mg/mL was aliquoted followed by dilution with 
PBS into three concentrations, 1/10 (1885 µg/mL), 1/50 (377µg/mL), and 1/100 
(188.5µg/mL) in order to test for the best concentration of OPG for our purposes. The 
total amount of OPG loaded into the microspheres was determined by the preferred 
target release of up to 1mg/kg/day. Because the ideal release is 28 days and an 
average adult male Sprague-dawley rat weighs 0.350 kg, the total loaded amount of 
OPG was targeted to be 980 micro-gm. For the first release assay, a 50/50 mixture of a 
PEG with molecular weight of 750 Da and PBS was used for the fabrication of 
hydrogels. For the second release assay, a 50/50 combination of high molecular weight 
13
PEGDMA 750 Da and low molecular weight PEGDMA 200 Da diluted to a concentration 
of 1.5% with PBS was tested. The photoinitiator was made by measuring 100 mg of 
DMPA on a mg scale for accuracy and dissolved in 1 mL of 1-vinyl-2-pyrolidinone in a 
vial to make 100 mg/ml. A 50/50 solution of PEG-DMA/OPG was made by adding 500 
µliters of 750 mg PEG to 500 microliters of OPG. Then, 100 µliters of photoinitiator was 
added to the PEG OPG mixture followed by sonication for 5 minutes. A similar process 
was performed for the second release assay. 
Once the hydrogels were fabricated, 5 microliters were retrieved for cell counting. 
The spheres were then divided equally into 8 separate tubes with 1 million spheres/ml 
to carry out the assay. Each tube was centrifuged for 5 minutes at 2000 RPM. The 
solutions were washed twice with PBS. Following, the microspheres were immersed in 
275 microliters of PBS, sealed and placed in an incubator shaker set at 37°C for daily 
sampling of the supernatant to quantify the protein release.  
To establish in vitro OPG release kinetics, the supernatant was collected daily for 
28 days. The tubes were centrifuged for 5 minutes at 2000 RPM following which 250µL 
of supernatant was retrieved from each vial and stored in a freezer (-80°C). The tubes 
were then replenished with 250 µl of PBS and placed back into the incubator shaker at 
-37°C. After 28 days of daily supernatant collection, a micro bicinchoninic acid (µBCA) 
assay  was conducted to measure the daily OPG protein release (Thermoscientific) as 
per manufacturer's instructions. Based on release from initial prototypes, we made 
adjustments to the OPG formulations in the type and molecular weight of the PEG used 
to achieve the desired rate of 1mg/kg of OPG over 28 days (as determined by the 
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current effective dose of 1 mg/kg OPG in 350 gm rats).  For 1mg/kg to be delivered over 
28 days, the target release rate of an average male rate is 11.7µg/day. 
Thin Film Device Fabrication 
 Given that thin film devices have never been used in an oral environment, a 
specific design was required that would remain securely in place and be positioned 
away from biting forces, while successfully delivering the drug into the permeable 
tissues. The film needed to be large enough to be loaded with sufficient amounts of the 
drug. Thus, to maximize the loading of OPG and surface area of the film, the device 
was designed (Fig. 10 ) to spread across the palatal surface due to this being the 
largest non-biting surface in the rat oral cavity. To fabricate the films, slot casting 
methods were used. First, a glass plate was solvent cleaned with acetone, methanol, 
and isopropyl alcohol (IPA). Second, A 1:1 ratio of PEG and PCL were dissolved in the 
amount of 150 mg per ml of2,2,2,-trifluoroethanol (TFE). Lastly, the PEG/PCL/TFE 
solution was poured onto the cleaned glass plate and casting was performed with a 
clearance applicator with pre-determined thicknesses. With the clearance applicator, a 
15 mil film was made. The casted thin film was then placed in milli-q water for 24 hours 
to dissolve the PEG solution (i.e., porogen leaching) to form pores within the thin film. 
The porogen leached films were subjected to laser cutting to obtain the specific design 
for the rat oral cavity with a diameter of 11.3 mm wide including the arms, while the drug 
releasing portion was designed to be 4.4 mm to fit the roof of the mouth. A total of 95 ug 
of OPG at a concentration of 18.85 mg/mL was loaded into the films. The film was 
designed to have unidirectional drug transport with its porous side facing the palate to 
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allow drug release into the palatal mucosa, while the nonporous side composed of only 
PCL to face the oral cavity. For placement, it was bonded to the buccal surfaces of the 
second and third molars using dental adhesives.  After spin-casting and laser cutting, 
the films were loaded with OPG and heat sealed for immersion into PBS. The daily 
supernatant was collected to measure the release of OPG using µBCA as described 
previously for the PEG delivery system. 
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Results 
 In our first trial, we determined the OPG loading concentrations in PEG that 
would result in appropriate release of desired concentrations of OPG over a 7 day 
period. The microspheres were constructed with three concentrations of OPG at 1/10, 
1/50 and 1/100 dilution of the original OPG of 18.85 mg/ml. The protein release from the 
microspheres was determined every 24 hours using micro-BCA for 7 days (Fig. 11A). 
On the first day, an average of 176.00 ug/mL of OPG was released from the 1/10 diluted 
OPG solution, 101.11 ug/mL for the 1/50 solution, and 114.18 ug/mL for the 1/100 
solution. By day 4, the release began showing a more steady trend with 53.3ug/mL, 
18.63 ug/mL, and 19.05 ug/mL of OPG being released for the 1/10, 1/50, and 1/100 
solutions, respectively. Over the duration of 7 days on the average a total of 522.41 ug, 
239.60, and 281.70 ug of OPG were released respectively for the highest to lowest 
concentrations of OPG utilized (Fig. 11B). The graph shows a release burst followed by 
a decreased release of protein over 7 days.  
 After identifying that the highest concentration of OPG used (1/10 dilution or 188 
ug/ml) resulted in release in appropriate range of OPG, but given that this occurred 
relatively quickly over 7 days, we made modifications to the PEG in an attempt to 
achieve a slower and more sustained OPG release. For this experiment OPG (1/10 
dilutions) was encapsulated in microspheres fabricated with 50%PEGDMA750 and 50% 
PEGDMA200 (1.5%) and the release kinetics determined over 7 days (Fig. 12). This 
modification resulted in a more constant release in a range of 18-28 ug/mL with 
standard deviations ranging from 3.3 to 8.23 revealing a diminished burst release seen 
when using PEG by itself.  
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Thin Film Release Assay 
 The thin films were first tested with adhesives to determine the effects of the 
bond on the device. The devices were weighed on a milligram scale at 1, 3, 7, 14 and 
38 days after adhesive bonding. The average weight of the film remained stable at 
15mg before and after each allotted time period. No significant reduction in weight 
signifying degradation of the films was observed (Fig. 13).   
 Scanning electron microscopy was used to examine the surface topography to 
confirm  the integrity of the thin films after adhesive binding (Fig. 14A). The adhesives 
did not seep into the opposing side of the film (Fig. 14B), and a clear junction was noted 
on the designated adhesive region of the thin film and remained clear of the remainder 
of the film (Fig. 14C). 
Thin Film Protein Release Assay #1 
 The devices were loaded with 80-110 ug of OPG. No wash step was performed. 
The limitations of OPG loaded were due to size limitations of the device. On day 1, the 
three devices released 78ug, 88ug, and 99ug of OPG respectively (Fig. 15). In the 
following 3 days, less than 5ug was released per day.  
Thin film protein release assay #2 
 In the second thin film release assay, some modifications were made. The neck 
size of the film device was increased (Fig. 16) to allow for improved loading and 
prevention of load loss as seen in the results from the first round of release assays. In 
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addition, a pre-wash step was included for rinsing the films before elution. Three 
devices were loaded with 80-105 ug of OPG (Fig. 17).  Device 1 released 40ug of OPG 
on day 1 and then tapered off below 10 ug for the following 3 days. Device 2 
experienced a steady increase in protein release until day 2, having released a total of 
60 ug over three days. However on day 3, a negligible amount of protein was released, 
followed by another peak release of 25 ug on day 4. Device 3 experienced most of the 
release on day 1 of the experiment, followed by 3 days of negligible protein release.  
 Given the inconsistent results of protein release experienced with the thin films, 
scanning electron microscopy was performed to examine the binding surfaces of the 
films (Fig. 18). Porous structures were identified between the two surfaces of the thin 
film indicating the sealing process is impaired by human error.  
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Discussion 
 In these studies, we fabricated and tested in vitro potential drug delivery methods 
for use in orthodontic therapy including mitigating post-orthodontic relapse, which is a 
multifactorial and remains poorly understood. While we can attempt to predict which of 
our patients is more likely to experience relapse and take measures towards prevention, 
much of this process currently remains out of our control given that we currently rely on 
patient compliance during the several critical months it takes for bone stabilization to 
occur. Although the turnover and maturation of bone is only one of the components of 
retention, it is an important one and as seen in the medical field, we have developed 
successful means to promote it. Aside from orthodontic purposes, there is value in 
producing new methods to promote bone turnover and maturation in other aspects of 
dentistry, such as periodontology. In periodontology, methods for inhibiting the 
degeneration of bone and promoting regeneration of bone is of high value given the 
nature of the problems seen in patients with periodontal disease.  
 While we have developed methods to deliver OPG locally and found success in 
its ability to promote bone stabilization, we further aimed to explore methods of 
sustained release as well as noninvasive methods of delivery in this study. Specifically, 
we used the validated dose of OPG required to significantly improve post-orthodontic 
stability to develop methods for delivering that dose in a controlled manner over a long 
duration of time. We used microspheres composed of PEG which are known to be more 
effective than PLGA in controlling the delivery of proteins due to their chemical 
composition and interaction with the body. The specific composition of PEG needed for 
our purposes was unknown and required a few trials before it could be determined. In 
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our first attempt we had to test two variables— the concentration of OPG that would 
produce appropriate release profiles with PEG to achieve our target release per day of 
0.5 mg/kg, and the type of PEG that would produce a consistent controlled release. We 
used three concentrations of OPG (1/10, 1/50, 1/100) and a high molecular weight (750) 
PEG. The results seen in Figure 10 reveal a burst release experienced by all three 
groups. Each concentration group experienced between 51.11-126 ug more protein 
released than the target release of 50 ug on day 1. This burst release was likely due to 
the inability of the microspheres to contain the OPG. In addition, because all three 
concentrations of OPG showed similar release kinetics, and therefore, appropriate 
reactions with PEG, we were able to eliminate the need of multiple concentrations of 
OPG for the subsequent  trials.  
 The retention of OPG in the microspheres required improvement in order to 
achieve the target release of 50ug/day. Previous studies have shown that reducing the 
molecular weight of PEG can reduce the diffusivity of proteins from the microspheres.40 
Decreasing molecular weight of PEG allows us to increase the number of PEG 
molecules, which in return, increases crosslinkable double bonds. The increased 
strength from the double bonds provides a stronger structure which reduces diffusivity.40   
Thus, lower molecular weight PEG microspheres expel their contents in a more 
controlled fashion. For this reason, we combined 50% molecular weight PEG200(1.5%) 
with 50% of the original higher molecular weight PEG (750) to create a mixture for the 
second batch of hydrogels. The data resulting from this modification revealed a much 
more steady release of OPG ranging between 18-28ug/day. Although the amount 
released per day was lower than our target release of 50 ug/kg, we find this to be 
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beneficial because although much of the bone maturation processes occur within the 
first 30 days, the process continues for up to 6 months. With this in mind, it is likely  
beneficial to have the lower dose spread over a longer period of time. Thus this delivery 
method holds promise for future studies to confirm their release kinetics in vitro and 
efficacy tests in vivo.  
Thin Films 
To begin, we needed to ensure that the dental adhesives which would be used 
with the thin film design would not dissolve the films due to their acidic nature. To do so, 
the adhesives were placed on the films and co-incubated for 1-30 days in PBS. They 
were removed from PBS and lyophilized on days 1,3,7,14, and 30 to remove the 
residual PBS and to weigh the films. Because the results revealed no changes in 
weight, we can conclude that there was no degradation of the thin film devices. This 
confirmation allowed us to move forward with the current design of the thin film device.   
To visualize and confirm the integrity of the thin films adhesive binding, scanning 
electron microscopy was used. Figure 14A shows an SEM that was taken of the side of 
the films where the dental adhesives were placed. Here, we can appreciate the 
architecture of the dental adhesives for a frame of reference for when we examine the 
opposite side of the film (Figure 14B) without dental adhesives. This image allows us to 
confirm that the adhesives do not seep through the film and that the coincubation of the 
films with the adhesives is not affected by the adhesives. Lastly, In Figure 14C, a clear 
junction was noted on the designated adhesive region of the thin film and remained 
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clear of the remainder of the film. This again confirms that the adhesive stays in place, 
and does not seep through to the rest of the film.  
The maximum amount of OPG we were able to load into the thin film devices 
was 80-110ug of OPG. This presented as our first limitation to thin film protein delivery. 
Although we designed the largest possible thin film for a rat’s intraoral cavity, we need to 
be able to load a significant amount more in order to reach our target release of 50 ug/
kg/day. 
 In our first release assay, no wash step was performed. On day 1, the three 
devices released 78ug, 88ug, and 99ug of OPG respectively. During the following 3 
days, less than 5ug was released per day. These results indicate that much of the 
protein was lost on the surface of the thin films indicated by the burst release. To 
improve the release and limit the loss of OPG, a wash step was added. In addition, the 
loading of the OPG into the films was a difficult step due to the physical constraints of 
the neck size of the films.  
In the second protein release assay, the neck size of the films were increased 
and the films were prewashed before elution. Three devices were loaded with 90ug of 
protein and assayed for protein release for 4 days. On day 0, the amount of protein lost 
in the wash was observed to be between 5ug-25ug. Device 1 released most of its 
protein (60ug) on day 1, followed by insignificant amounts of protein for the remaining 
days. Device 2 presented the most promising release of protein with 20-30ug/day, 
except for day 3 when a very small amount of protein was released (<5ug). Device 3 
presented very similarly to device 1 by minimal protein being lost in the wash step 
(<5ug)  and the majority of protein released on day 1 (60ug). In this assay, we largely 
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improved the loss of the protein by increasing the neck size and including the wash 
step. However, the varying results of the assay suggest that the technique of thin film 
fabrication requires improvement. To determine which step required improvement, we 
examined the seal of the thin films by SEM. In Figure 18, the interface where the porous 
and nonporous sides of the films are sealed together is shown. This image reveals 
pores in that interface suggesting flaws in the sealing step of thin film fabrication. This 
step is currently a limitation in nanotechnology and needs further optimization. 
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Conclusion 
While we have developed methods to deliver OPG locally and found success in 
its ability to promote bone stabilization, we further explored methods of sustained 
release as well as noninvasive methods of delivery in this study. Osteoprotegerin 
released by 50%PEGDMA250(1.5%) 50%PEGDMA750 microspheres could provide a 
more controlled release than the previously studied methods of release. Thin film 
devices may also provide a completely non-invasive approach to delivering OPG, but 
require further improvements in the sealing process. 
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Future Directions 
 The OPG release in 50%PEGDMA250(1.5%) 50%PEGDMA750 microspheres 
should be confirmed with a 30 day release assay followed by an ELISA to confirm the 
protein did not denature during microsphere fabrication. Following this confirmation, the 
microspheres should be tested in the animal model we have proposed in Figures 1, 2 
and 7. The thin films remain a viable option but require extensive improvements in the 
sealing process. In addition, the amount of protein loaded into the microspheres needs 
to be increased in order to meet the target release of protein per day. It is possible that 
flash freezing the proteins to reconstitute them at a higher concentration before loading 
the films may be one solution.    
26
Bibliography 
1. Ashcraft MB, Southard KA, Tolley EA. The effect of corticosteroid-induced 
osteoporosis on orthodontic tooth movement. Am. J. Orthod. Dentofacial Orthop. 
1992;102(4):310–9. 
2. Asiry MA. Biological aspects of orthodontic tooth movement: A review of literature. 
Saudi J. Biol. Sci. 2018;25(6):1027–32. 
3. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and 
remodeling. Arch. Biochem. Biophys. 2008;473(2):139–46. 
4. Alhashimi N, Frithiof L, Brudvik P, Bakhiet M. Orthodontic tooth movement and de 
novo synthesis of proinflammatory cytokines. Am. J. Orthod. Dentofacial Orthop. 
2001;119(3):307–12. 
5. Karsenty G. The complexities of skeletal biology. Nature 2003;423(6937):316–8. 
6. Yasuda H, Shima N, Nakagawa N, et al. A novel molecular mechanism modulating 
osteoclast differentiation and function. | Semantic Scholar. undefined 1999. 
7. McCormack SW, Witzel U, Watson PJ, Fagan MJ, Gröning F. The biomechanical 
function of periodontal ligament fibres in orthodontic tooth movement. PLoS ONE 
2014;9(7):e102387. 
8. Will LA. Orthodontic tooth movement: A historic prospective. Front. Oral Biol. 
2016;18:46–55. 
9. Igarashi K, Mitani H, Adachi H, Shinoda H. Anchorage and retentive effects of a 
bisphosphonate (AHBuBP) on tooth movements in rats. Am. J. Orthod. Dentofacial 
27
Orthop. 1994;106(3):279–89. 
10. Hayashi K, Igarashi K, Miyoshi K, Shinoda H, Mitani H. Involvement of nitric oxide in 
orthodontic tooth movement in rats. Am. J. Orthod. Dentofacial Orthop. 2002;122(3):
306–9. 
11. Dolce C, Vakani A, Archer L, Morris-Wiman JA, Holliday LS. Effects of echistatin and 
an RGD peptide on orthodontic tooth movement. J. Dent. Res. 2003;82(9):682–6. 
12. Holliday LS, Vakani A, Archer L, Dolce C. Effects of matrix metalloproteinase 
inhibitors on bone resorption and orthodontic tooth movement. J. Dent. Res. 2003;82(9):
687–91. 
13. Kanzaki H, Chiba M, Takahashi I, Haruyama N, Nishimura M, Mitani H. Local OPG 
gene transfer to periodontal tissue inhibits orthodontic tooth movement. J. Dent. Res. 
2004;83(12):920–5. 
14. Dunn MD, Park CH, Kostenuik PJ, Kapila S, Giannobile WV. Local delivery of 
osteoprotegerin inhibits mechanically mediated bone modeling in orthodontic tooth 
movement. Bone 2007;41(3):446–55. 
15. Hudson JB, Hatch N, Hayami T, et al. Local delivery of recombinant osteoprotegerin 
enhances postorthodontic tooth stability. Calcif. Tissue Int. 2012;90(4):330–42. 
16. Schneider DA, Smith SM, Campbell C, Hayami T, Kapila S, Hatch NE. Locally 
limited inhibition of bone resorption and orthodontic relapse by recombinant 
osteoprotegerin protein. Orthod. Craniofac. Res. 2015;18 Suppl 1:187–95. 
17. Sydorak I, Dang M, Baxter SJ, et al. Microsphere controlled drug delivery for local 
control of tooth movement. Eur. J. Orthod. 2018;41(1):1–8. 
28
18. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of 
a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res. 
2001;16(2):348–60. 
19. Body J-J, Greipp P, Coleman RE, et al. A phase I study of AMGN-0007, a 
recombinant osteoprotegerin construct, in patients with multiple myeloma or breast 
carcinoma related bone metastases. Cancer 2003;97(3 Suppl):887–92. 
20. Capparelli C, Morony S, Warmington K, et al. Sustained antiresorptive effects after a 
single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic 
and pharmacokinetic analysis in rats. J. Bone Miner. Res. 2003;18(5):852–8. 
21. Morony S, Capparelli C, Lee R, et al. A chimeric form of osteoprotegerin inhibits 
hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 
1, 25(OH)2D3. J. Bone Miner. Res. 1999;14(9):1478–85. 
22. Teng YT, Nguyen H, Gao X, et al. Functional human T-cell immunity and 
osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J. Clin. 
Invest. 2000;106(6):R59-67. 
23. Jha AK, Yang W, Kirn-Safran CB, Farach-Carson MC, Jia X. Perlecan domain I-
conjugated, hyaluronic acid-based hydrogel particles for enhanced chondrogenic 
differentiation via BMP-2 release. Biomaterials 2009;30(36):6964–75. 
24. Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable 
Controlled Drug Delivery Carrier. Polymers (Basel) 2011;3(3):1377–97. 
25. Peña JR, Pinney JR, Ayala P, Desai TA, Goldspink PH. Localized delivery of 
mechano-growth factor E-domain peptide via polymeric microstructures improves 
29
cardiac function following myocardial infarction. Biomaterials 2015;46:26–34. 
26. Doroudian G, Pinney J, Ayala P, Los T, Desai TA, Russell B. Sustained delivery of 
MGF peptide from microrods attracts stem cells and reduces apoptosis of myocytes. 
Biomed. Microdevices 2014;16(5):705–15. 
27. Teekamp N, Van Dijk F, Broesder A, et al. Polymeric microspheres for the sustained 
release of a protein-based drug carrier targeting the PDGFβ-receptor in the fibrotic 
kidney. Int. J. Pharm. 2017;534(1–2):229–36. 
28. Jiang W, Schwendeman SP. Stabilization and controlled release of bovine serum 
albumin encapsulated in poly(D, L-lactide) and poly(ethylene glycol) microsphere 
blends. Pharm. Res. 2001;18(6):878–85. 
29. Deveza L, Ashoken J, Castaneda G, et al. Microfluidic Synthesis of Biodegradable 
Polyethylene-Glycol Microspheres for Controlled Delivery of Proteins and DNA 
Nanoparticles. ACS Biomater. Sci. Eng. 2015;1(3):157–65. 
30. Yu B, Cong H, Liu X, et al. Preparation of monodisperse PEG hydrogel composite 
microspheres via microfluidic chip with rounded channels. J. Micromech. Microeng. 
2013;23(9):095016. 
31. Jain E, Sheth S, Polito K, Sell SA, Zustiak SP. Storage stability of biodegradable 
polyethylene glycol microspheres. Mater. Res. Express 2017;4(10):105403. 
32. Bernards DA, Desai TA. Nanotemplating of biodegradable polymer membranes for 
constant-rate drug delivery. Adv Mater Weinheim 2010;22(21):2358–62. 
33. Lance KD, Good SD, Mendes TS, et al. In Vitro and In Vivo Sustained Zero-Order 
Delivery of Rapamycin (Sirolimus) From a Biodegradable Intraocular Device. Invest. 
30
Ophthalmol. Vis. Sci. 2015;56(12):7331–7. 
34. Lance KD, Bernards DA, Ciaccio NA, et al. In vivo and in vitro sustained release of 
ranibizumab from a nanoporous thin-film device. Drug Deliv. Transl. Res. 2016;6(6):
771–80. 
35. Kim J, Kudisch M, Mudumba S, et al. Biocompatibility and pharmacokinetic analysis 
of an intracameral polycaprolactone drug delivery implant for glaucoma. Invest. 
Ophthalmol. Vis. Sci. 2016;57(10):4341–6. 
36. Kim J, Kudisch M, da Silva NRK, et al. Long-term intraocular pressure reduction 
with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma 
agent. J. Control. Release 2018;269:45–51. 
37. Bernards DA, Bhisitkul RB, Wynn P, et al. Ocular biocompatibility and structural 
integrity of micro- and nanostructured poly(caprolactone) films. J. Ocul. Pharmacol. 
Ther. 2013;29(2):249–57. 
38. Nyitray CE, Chang R, Faleo G, et al. Polycaprolactone Thin-Film Micro- and 
Nanoporous Cell-Encapsulation Devices. ACS Nano 2015;9(6):5675–82. 
39. Chang R, Faleo G, Russ HA, et al. Nanoporous Immunoprotective Device for Stem-
Cell-Derived β-Cell Replacement Therapy. ACS Nano 2017;11(8):7747–57. 
40. Lee S, Tong X, Yang F. Effects of the poly(ethylene glycol) hydrogel crosslinking 
mechanism on protein release. Biomater. Sci. 2016;4(3):405–11. 
31
List of Figures 
Figure 1. Appliance placement. Niti coil spring from maxillary molars to incisors. 
 
Figure 2: Animal study timeline of procedures 
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 Figure 3. PLGA microsphere cumulative release assay  
 
  
Figure 4. Examples of thin film device types and sizes.   
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 Figure 5. Fabrication of planar thin film devices 
 
Figure 6. In vitro release of fluoroscein isothiocyanate-labeled bovine serum albumin 
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Figure 7. Schematic of study design for in vivo testing of the efficacy of osteogenic or 
anti-osteolytic drug delivery systems.  
 
Figure 8. Representation of 3D volume to be utilized for determining intraradicular bone 
quality using micro-CT. 
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Figure 9: Axial section through the rat first molar roots and maxillary alveolus. (A) Low 
power HE staining to demonstrating five roots and intraradicular bone sites that will be 
analyzed for bone formation, and bone and root resorption. (B) High power image 
showing root resorption pit. (C) TRAP positive staining of multinucleated cells will be 
quantitated for bone and root resorptive activity. (IB=intraradicular bone; P=periodontal 
ligament; MP=mesiopalatal root; DB=distobuccal root; OC=TRAP positive osteoclasts) 
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Figure 10. Thin film device for placement on rat palate.  
 
Figure 11. Daily (A) and cumulative (B) release of protein (OPG) from PEG 
microspheres for three concentrations of OPG (1/10 dilution or 1885 ug/ml; 1/50 dilution 
or 377 ug/ml and 1/100 dilution of 188.5 ug/ml OPG) over a 7 day duration.  
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Figure 12. Daily release of OPG from 250%PEGDMA750 and 50% PEGDMA200(1.5%) 
microspheres over 7 days using 1/10 dilution of OPG. 
 
Figure 13. Coincubation of Thin Films with adhesives does not affect device weight.  
 
14.1 
38
 
14.2 
 
14.3 
Figure 14: SEM photomicrographs of composite-Thin Film interface.  14.1.  Composite 
architecture on composite side of Thin Film device.  14.2 Architecture of thin film on 
non-composite side of Thin Film device. 14.3.  High power photomicrograph of 
composite and thin film interface. 
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Figure 15. Thin Film Release Assay 1 
 
Figure 16. Neck size increased in 2nd thin film device design. 
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Figure 17. Thin film release assay 2.  
 
Figure 18. Porous and non-porous interface of fabricated Thin Films demonstrate 
inadequate sealing of the device.  
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